Anthem Biosciences Limited
812.15
INR
+10.35
(+1.29%)
Anthem Biosciences Limited
BSE:ANTHEM
(Bombay Stock Exchange)
Recent
price
812.15
P/E
ratio
75.15
div
yld
- -
ROIC.AI
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.- Similar Companies
- Business
- Anthem Biosciences Ltd. (ANTHEM.NS) operates as an innovation-driven, technology-focused contract research, development, and manufacturing organization (CRDMO) with fully integrated operations spanning drug discovery, development, and commercial manufacturing across New Chemical Entity (NCE) and New Biological Entity (NBE) programs. The company provides end-to-end services including medicinal chemistry, preclinical research, in vitro and in vivo testing, process development, clone development, antibody-drug conjugates, RNA interference platforms, peptides, lipids, oligonucleotides, GMP synthesis from milligram to multi-ton scale, quality control, analytical development, stability studies, and regulatory support; it also manufactures and sells specialty ingredients such as active pharmaceutical ingredients (APIs) like Cabergoline, Calcium Folinate, L-Methyl Tetrahydrofolate Calcium, Ormeloxifene, Pancreatin, Papain, Pyridoxal-5-Phosphate, Serratiopeptidase, Valganciclovir, and Voglibose, alongside nutraceuticals for human nutrition (e.g., Alpha GPC, Resveratrol, probiotics including Bacillus clausii and Lactobacillus rhamnosus), enzymes (e.g., Alpha Galactosidase, Amylase), animal nutrition products, and industrial applications in food, feed, textiles, and biofuels. Anthem serves a diverse global customer base of over 150 clients, including emerging biotech firms, small to mid-sized pharmaceutical companies, and large innovator pharma, with a focus on high-growth areas like GLP-1 agonists (e.g., Semaglutide, Liraglutide), anti-infectives, and biosimilars; operations span the United States (89 customers via partnerships), Europe, Japan, and other regions, supported by cGMP facilities inspected by USFDA, PMDA, and EU QPs. Founded in 2006 and headquartered in Bengaluru, India, at No. 49, Canara Bank Road, Electronics City Phase 1, the company completed India's largest CRDMO initial public offering (IPO) in July 2025, achieving the highest revenue growth from fiscal 2024 to 2025 among peers, and maintains a strategic U.S. sales partnership with DavosPharma (an affiliate of shareholder Portsmouth LLC) to onboard emerging biotech customers; its pipeline includes 242 projects (68 in discovery, 145 in early development, 16 in late-stage) as of March 31, 2025.